PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs.

医学 药理学 重症监护医学 药物开发 临床试验 生物信息学 化学
作者
M. Maneiro,E. De Vita,Daniel Conole,Cyrille S Kounde,Q Zhang,Edward W. Tate
出处
期刊:Progress in Medicinal Chemistry 卷期号:60: 67-190 被引量:4
标识
DOI:10.1016/bs.pmch.2021.01.002
摘要

The vast majority of currently marketed drugs rely on small molecules with an 'occupancy-driven' mechanism of action (MOA). Therefore, the efficacy of these therapeutics depends on a high degree of target engagement, which often requires high dosages and enhanced drug exposure at the target site, thus increasing the risk of off-target toxicities (Churcher, 2018 [1]). Although small molecule drugs have been successfully used as treatments for decades, tackling a variety of disease-relevant targets with a defined binding site, many relevant therapeutic targets remain challenging to drug due, for example, to lack of well-defined binding pockets or large protein-protein interaction (PPI) interfaces which resist interference (Dang et al., 2017 [2]). In the quest for alternative therapeutic approaches to address different pathologies and achieve enhanced efficacy with reduced side effects, ligand-induced targeted protein degradation (TPD) has gained the attention of many research groups both in academia and in industry in the last two decades. This therapeutic modality represents a novel paradigm compared to conventional small-molecule inhibitors. To pursue this strategy, heterobifunctional small molecule degraders, termed PROteolysis TArgeting Chimeras (PROTACs) have been devised to artificially redirect a protein of interest (POI) to the cellular protein homeostasis machinery for proteasomal degradation (Chamberlain et al., 2019 [3]). In this chapter, the development of PROTACs will first be discussed providing a historical perspective in parallel to the experimental progress made to understand this novel therapeutic modality. Furthermore, common strategies for PROTAC design, including assays and troubleshooting tips will be provided for the reader, before presenting a compendium of all PROTAC targets reported in the literature to date. Due to the recent advancement of these molecules into clinical trials, consideration of pharmacokinetics and pharmacodynamic properties will be introduced, together with the biotech landscape that has developed from the success of PROTACs. Finally, an overview of subsequent strategies for targeted protein degradation will be presented, concluding with further scientific quests triggered by the invention of PROTACs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wangxiaoyu完成签到,获得积分10
刚刚
安静代萱完成签到 ,获得积分10
2秒前
小醉依然完成签到,获得积分20
2秒前
zp发布了新的文献求助10
2秒前
wangxiaoyu发布了新的文献求助10
3秒前
4秒前
星辰大海应助leez采纳,获得10
4秒前
77发布了新的文献求助10
4秒前
6秒前
柳子发布了新的文献求助10
8秒前
monster发布了新的文献求助30
9秒前
Gaojin锦发布了新的文献求助10
9秒前
10秒前
陈住气完成签到,获得积分10
10秒前
杏林靴子完成签到,获得积分10
10秒前
gjww应助77采纳,获得10
11秒前
11秒前
13秒前
烟花应助24采纳,获得10
14秒前
15秒前
17秒前
leez发布了新的文献求助10
19秒前
20秒前
Betty发布了新的文献求助10
20秒前
HJin发布了新的文献求助10
23秒前
25秒前
在水一方应助娇娇采纳,获得10
25秒前
li关闭了li文献求助
26秒前
科研通AI2S应助铜豌豆小C采纳,获得10
27秒前
奔跑吧应助铜豌豆小C采纳,获得10
27秒前
田様应助南宫初三采纳,获得30
27秒前
忆往昔发布了新的文献求助20
29秒前
徐才完成签到,获得积分10
31秒前
LX完成签到,获得积分10
31秒前
33秒前
南孚阮桑应助2090采纳,获得20
33秒前
34秒前
35秒前
36秒前
37秒前
高分求助中
Heun’s Differential Equations 600
《Fundamentals of Power Supply Design》Robert A. Mammano 510
High Wire: How China Regulates Big Tech and Governs Its Economy 260
lingnan science journal vol. 16 250
The philosophy of sports medicine care: an historical review 250
A posteriori勾配制限手法「ポストリミタ」と界面捕獲法THINCを組み合わせた連続・不連続流れを高解像するMUSCLタイプの解法 210
Hybrid moth-flame optimisation algorithm with differential evolution for visual object tracking 200
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2251596
求助须知:如何正确求助?哪些是违规求助? 1900513
关于积分的说明 4743415
捐赠科研通 1690121
什么是DOI,文献DOI怎么找? 856890
版权声明 545565
科研通“疑难数据库(出版商)”最低求助积分说明 453834